

Policy Number	OTH903.028
Policy Effective Date	05/01/2026

Corneal Collagen Cross-Linking

Table of Contents
Coverage
Policy Guidelines
Description
Rationale
Coding
References
Policy History

Related Policies (if applicable)
None

Disclaimer

Carefully check state regulations and/or the member contract.

Each benefit plan, summary plan description or contract defines which services are covered, which services are excluded, and which services are subject to dollar caps or other limitations, conditions or exclusions. Members and their providers have the responsibility for consulting the member's benefit plan, summary plan description or contract to determine if there are any exclusions or other benefit limitations applicable to this service or supply. **If there is a discrepancy between a Medical Policy and a member's benefit plan, summary plan description or contract, the benefit plan, summary plan description or contract will govern.**

Coverage

Corneal collagen cross-linking using riboflavin and ultraviolet A **may be considered medically necessary** as a treatment of:

- Progressive keratoconus; or
- Corneal ectasia after refractive surgery.

NOTE: Two corneal collagen cross-linking products were available for treatment of progressive keratoconus and corneal ectasia – Photrexa and Epioxa. Photrexa products are planned to be discontinued from the market effective January 20, 2026, with manufacturing set to end February 2026.

Corneal collagen cross-linking using riboflavin and ultraviolet A **is considered experimental, investigational and/or unproven** for all other indications.

Policy Guidelines

The American Academy of Ophthalmology has not set forth definitive criteria defining progressive keratoconus but has suggested that signs of progression include changes in refraction, visual acuity and corneal shape. (1) In the trials leading to U.S. Food and Drug Administration (FDA) approval of corneal collagen cross-linking, progressive keratoconus or corneal ectasia were defined as one or more of the following:

- An increase of 1 diopter (D) in the steepest keratometry value,
- An increase of 1 D in regular astigmatism evaluated by subjective manifest refraction,
- A myopic shift (decrease in the spherical equivalent) of 0.50 D on subjective manifest refraction,
- A decrease ≥ 0.1 mm in the back optical zone radius in rigid contact lens wearers where other information was not available.

Description

Corneal collagen cross-linking is a photochemical procedure approved by the U.S. Food and Drug Administration (FDA) for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Keratoconus is a dystrophy of the cornea characterized by progressive deformation (steepening) of the cornea, while corneal ectasia is keratoconus that occurs following refractive surgery. Both conditions can lead to functional loss of vision and need for corneal transplantation.

Treatment of Keratoconus and Ectasia

The initial treatment for keratoconus often consists of hard contact lenses. A variety of keratorefractive procedures have also been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileusis, although generally, results of these techniques have been poor. Implantation of intrastromal corneal ring segments is an additive technique in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for penetrating keratoplasty. Penetrating keratoplasty (i.e., corneal grafting) is the last line of treatment. About 20% of patients with keratoconus will require corneal transplantation. All of these treatments attempt to improve the refractive errors but are not disease-modifying.

Treatment options for ectasia include intraocular pressure-lowering drugs and intracorneal ring segments. Frequently, penetrating keratoplasty is required.

None of the currently available treatment options for keratoconus and corneal ectasia halt the progression of the disease, and corneal transplantation is the only option available when functional vision can no longer be achieved.

Corneal collagen cross-linking has the potential to slow the progression of the disease. It is performed with the photosensitizer riboflavin (vitamin B2) and ultraviolet A irradiation. There are 2 protocols for corneal collagen cross-linking:

1. Epithelium-off corneal collagen cross-linking (also known as “epi-off”): In this method, about 8 mm of the central corneal epithelium is removed under topical anesthesia to allow better diffusion of the photosensitizer riboflavin into the stroma. Following de-epithelialization, a solution with riboflavin is applied to the cornea (every 1 to 3 minutes for 30 minutes) until the stroma is completely penetrated. The cornea is then irradiated for 30 minutes with ultraviolet A 370 nm, a maximal wavelength for absorption by riboflavin, while the riboflavin continues to be applied. The interaction of riboflavin and ultraviolet A causes the formation of reactive oxygen species, leading to additional covalent bonds (cross-linking) between collagen molecules, resulting in stiffening of the cornea. Theoretically, by using a homogeneous light source and absorption by riboflavin, the structures beyond a 400-µm thick stroma (endothelium, anterior chamber, iris, lens, retina) are not exposed to an ultraviolet dose that is above the cytotoxic threshold.
2. Epithelium-on corneal collagen cross-linking (also known as “epi-on” or transepithelial): In this method, the corneal epithelial surface is left intact (or may be partially disrupted) and a longer riboflavin loading time is needed.

Historically, the only corneal collagen cross-linking treatment approved by the U.S. FDA was the epithelium-off method. In 2025, the first epithelium-on corneal collagen cross-linking treatment was approved (riboflavin 5'-phosphate ophthalmic solution, 0.177% and 0.239%; Epioxa™). Epioxa is anticipated to enter the market during quarter 1 of 2026. Corneal collagen cross-linking is being evaluated primarily for corneal stabilization in patients with progressive corneal thinning, such as keratoconus and corneal ectasia following refractive surgery. Corneal collagen cross-linking may also have anti-edematous and antimicrobial properties.

Regulatory Status

In 2016, riboflavin 5'-phosphate in 20% dextran ophthalmic solution (Photrex Viscous™; Avedro, now Glaukos) and riboflavin 5'-phosphate ophthalmic solution (Photrex™; Avedro) were approved by the FDA for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia after refractive surgery. (2) In 2025, riboflavin 5'-phosphate 0.177% and 0.239% ophthalmic solution (Epioxa™ and Epioxa HD™; Glaukos) was approved for treatment of keratoconus in adults and children aged 13 years and older. Epioxa uses the O₂n System™ and Boost Googles® for its proprietary epithelium-on corneal collagen cross-linking technology. Photrex products are planned to be discontinued from the market effective January 20, 2026, with manufacturing set to end February 2026.

Rationale

Medical policies assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life, and ability to function including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or

worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and the quality and credibility. To be relevant, studies must represent one or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Corneal Collagen Cross-Linking for Keratoconus

Clinical Context and Therapy Purpose

Keratoconus is a bilateral dystrophy characterized by progressive ectasia (paracentral steepening and stromal thinning) that impairs visual acuity. While frequently diagnosed at a young age, the progression of keratoconus is variable. Results from a longitudinal study of over 900 patients with keratoconus showed that there was a decrease of 2 high- and 4 low-contrast letters in best-corrected visual acuity over 7-years follow-up. (3, 4) About 1 in 5 patients showed a decrease of 10 or more letters in high-contrast visual acuity and one-third of patients showed a decrease of 10 or more letters in low-contrast visual acuity.

The purpose of corneal collagen cross-linking using riboflavin and ultraviolet A irradiation in individuals with keratoconus is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with progressive keratoconus.

Intervention

The treatment being considered is corneal collagen cross-linking with riboflavin and ultraviolet A irradiation, which is performed by an ophthalmologist in an outpatient clinical setting.

Comparators

The comparators of interest are observation, rigid or specialty contact lens, intracorneal ring segments, or corneal transplant.

Outcomes

The outcomes of interest are change in disease status, functional outcomes, and treatment-related morbidity. Positive outcomes include slowing of disease progression and improvement in visual acuity and other ocular measurements. Negative outcomes include infection, adverse reactions, and need for alternative treatment, including corneal transplant.

Follow-up of at least 1 year is needed to assess outcomes.

Visual Acuity Definitions

Best spectacle-corrected visual acuity is the best vision correction that can be achieved with glasses as measured on the standard Snellen eye chart.

Best corrected visual acuity is the best vision correction that can be achieved with *any* visual correction (e.g., glasses, contact lenses, keratotomy) as measured on the standard Snellen eye chart.

Uncorrected visual acuity is the vision correction without visual correction as measured on the standard Snellen eye chart.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

1. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
2. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
3. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
4. Studies with duplicative or overlapping populations were excluded.

Epithelium-on Corneal Collagen Cross-Linking

Randomized Controlled Trials

The approval of Epioxa™ for epithelium-on corneal collagen cross-linking in patients with keratoconus was based on 2 sham-controlled RCTs (total N=592 eyes) that are summarized in the prescribing information but remain unpublished. (5) The primary efficacy endpoint was assessed at 6 months and 12 months post-treatment in the first and second studies, respectively. In the first study, change from baseline to 6 months in maximum corneal curvature was significantly better with corneal cross-linking than sham treatment ($p<.01$). In the second study, change from baseline to 12 months in maximum corneal curvature was significantly better with corneal cross-linking than sham treatment ($p<.01$). Changes in visual acuity are not presented in the prescribing information.

Epithelium-off Corneal Collagen Cross-Linking

Systematic Reviews

A 2024 ophthalmic technology assessment from the American Academy of Ophthalmology reviewed the safety and efficacy of epithelium-off corneal collagen cross-linking for progressive

corneal ectasia. (6) The analysis included 6 RCTs: 5 on progressive keratoconus (including Hersh et al. 2017 [summarized below]) and 1 on post-laser refractive surgery ectasia, with a mean follow-up of 2.4 years (range, 1 to 5 years). Although results were not statistically pooled, all studies reported reduced disease progression in treated patients versus controls and complications were rare. Treatment groups showed improvements in maximum keratometry (Kmax), corrected distance visual acuity, and uncorrected distance visual acuity. Corneal thickness decreased in both groups but was more pronounced in the treatment group.

McAnena et al. (2017) reported on the results of a systematic review and a meta-analysis assessing the efficacy of corneal collagen cross-linking treatment for keratoconus in pediatric patients. (7) A total of 13 articles, published between May 2011 and December 2014, examining 490 eyes of 401 patients (mean age, 15.25 years), were included in the meta-analysis. Bias assessment of individual studies was not included. Reviewers reported a significant improvement in best-corrected visual acuity at 6 months (standardized mean difference [SMD], -0.66; 95% confidence interval [CI], -1.22 to -0.11; $p=.02$), which was maintained at 1 year (SMD, -0.69; 95% CI, -1.15 to -0.22; $p<.01$). Two-year data were available for 3 studies (N=131 eyes) and the improvement in best-corrected visual acuity remained significant (SMD, -1.03; 95% CI, -2 to -0.06; $p=.04$).

Randomized Controlled Trials

Hersh et al. (2017) reported combined results from 2 open-label trials which informed FDA approval of Photrexa for epithelium-off corneal collagen cross-linking for treatment of keratoconus. (8) The studies randomized 205 patients to corneal collagen cross-linking ($n=102$) or a sham procedure ($n=103$). At 1 year follow-up, those in the treatment group had a significant decrease in maximum corneal curvature score (-1.6 diopters [D]) compared with baseline, while the control group saw an increase in maximum corneal curvature (1.0); the between-group difference in maximum corneal curvature change was 2.6 D ($p<.001$). Mean corrected distance visual acuity improved significantly more in the treatment group (5.7 Logarithm of the Minimum Angle of Resolution [logMAR]) than in the control group (2.2 logMAR; between-group difference, 3.5 logMAR; $p<.01$). A similar finding, though statistically insignificant, was observed for mean uncorrected distance visual acuity, with the treatment group improving by 4.4 logMAR, compared with the control group (2.6 logMAR; between-group difference, 1.8 logMAR). Endothelial cell count did not change significantly from baseline to 1 year in either group. Symptom and quality of life measures that were significantly improved from baseline at 1-year follow-up included reductions in difficulty driving, difficulty reading, double vision, vision fluctuations, glare and foreign body sensations in the corneal collagen cross-linking group; outcomes for the sham group were not reported. The trial was limited in that patients in the control group were allowed to switch to corneal collagen cross-linking treatment after 3 months; thus, their data were imputed based on the last observation carried forward method. Also, in the control group, patients did not undergo removal of their epithelium.

Nonrandomized Studies

Longer-term follow-up ranging from 2 to 10 years has been reported in cohort studies and case series conducted in Europe, where corneal collagen cross-linking has been performed for a greater number of years. Indications for treatment typically include progression of steepening (increase in maximum corneal curvature by at least 1 D in 1 year), deteriorating visual acuity, or the need to be fitted for new contact lenses more than once in 2 years. The largest and longest series to date are described next.

Toprak et al. (2017) retrospectively analyzed 29 eyes from pediatric patients (age range, 10 to 17 years) whose progressive keratoconus was treated with unilateral corneal collagen cross-linking treatment. (9) From baseline to 2-year follow-up, there was a significant decrease in mean corrected distance visual acuity (0.34 to 0.13 logMAR; $p < .001$). Maximum keratometry measures decreased from baseline 54.65 to 53.25 at 2 years ($p = .034$), while anterior chamber parameters, corneal thickness, and corneal volume were not significantly affected by corneal collagen cross-linking after 2 years ($p > .05$). Several parameters of the Scheimpflug imaging system were improved following corneal collagen cross-linking treatment: index of surface variance decreased from 69.75 at baseline to 62.95 at 2 years ($p = .004$); keratoconus index decreased from 1.16 to 1.14 ($p = .001$); center keratoconus index decreased from 1.05 to 1.04 ($p = .004$); and index of height decentration decreased from 0.056 to 0.042 ($p = .001$). The radius of minimum curvature increased significantly from baseline to 2 years (6.21 to 6.36; $p = .007$), although 2 other indices (indices of height and vertical asymmetry) did not change significantly. The authors noted that follow-up beyond 2 years is required to make long-term assessments of corneal collagen cross-linking as a treatment for keratoconus but concluded that their results seemed favorable for postoperative outcomes.

Badawi et al. (2017) published a prospective nonrandomized observational study of accelerated corneal collagen cross-linking to treat pediatric patients with keratoconus. (10) Of the 25 patients (33 eyes) enrolled, 80% were male, and most patients ($n = 17$) received unilateral corneal collagen cross-linking, administered with VibeX Rapid solution and Vega CBM X-Linker. The group's mean unaided and aided visual acuity were significantly improved at all time points (3, 6, and 12 months). At 12-month follow-up, the mean unaided visual acuity score was 0.34, which was a significant decrease compared with the preoperative mean score (0.54; $p < .001$). For aided visual acuity, there was a similar decrease from preoperative (0.36) to 12-month (0.17) time points ($p < .001$). Mean corneal astigmatism values also decreased significantly (preoperative 2.4 D decreased to 2.01 D at 12 months; $p < .001$). The mean maximum corneal curvature showed an average flattening of 1.2 D in 1 year (49.12 D decreasing to 47.9 D; $p < .001$); the authors reported significant improvements in other measures such as central pachymetry, maximum anterior elevation, average progression indices, and Q values. A limitation of the study was the slight increase observed in posterior surface elevation, which, contrary to other study measures, showed no significant positive effect 12 months after accelerated corneal collagen cross-linking ($p = .9$). Advising further study of the procedure, the authors noted that the unusual result might be accounted for by the choice of Pentacam as a corneal analysis tool because there might have been corneal artifacts present during the evaluation.

Knutsson et al. (2018) published a prospective cohort study of 43 patients (52 eyes) between the ages of 12 and 17 years who underwent corneal collagen cross-linking as a treatment for keratoconus in one or both eyes. (11) Two-year outcomes were reported for all patients, although longer-term (up to 7 years) follow-up was available for 21 eyes. At 2 years, overall mean maximum corneal curvature decreased from 59.30 ± 7.08 to 57.07 ± 6.46 ($p < .001$), and overall mean uncorrected visual acuity and best spectacle-corrected visual acuity decreased, although not significantly. Additional analyses were conducted of patients whose eyes had maximum corneal curvature values of 60 D or greater ($n=25$), compared with those whose keratometry was less severe (<60 D). As with the overall findings, mean maximum corneal curvature were significantly decreased for both cohorts, while neither uncorrected visual acuity nor best spectacle-corrected visual acuity measures changed significantly at 1 or 2 years. In patients with advanced keratoconus, mean maximum corneal curvature decreased from 64.94 (95% CI, 62.94 to 66.94) to 62.25 (95% CI, 60.55 to 63.95) at 2 years ($p < .001$); for the less-advanced cohort, mean maximum corneal curvature decreased from 53.88 (95% CI, 52.48 to 55.28) at baseline to 52.08 (95% CI, 50.68 to 53.48) at 2 years ($p < .001$). While most findings were favorable for the efficacy of corneal collagen cross-linking in treating even severe keratometry, the authors noted that the study was limited by the use of 2 pachymetric measurement techniques (optical coherence tomography and ultrasound) rather than a single technique across the study. Further, the lack of full long-term data for all patients limited the study to reporting only 2-year outcomes.

Papaoiou et al. (2016) retrospectively analyzed 377 eyes of 336 patients (mean age, 15 years) who underwent corneal collagen cross-linking for progressive keratoconus. (12) There was a significant improvement in mean best spectacle-corrected visual acuity from 0.33 to 0.27 logMAR ($p < .05$). The authors found that the benefits of corneal collagen cross-linking in stabilizing keratoconus were maintained for more than 2 years in most pediatric eyes.

Padmanabhan et al. (2017) published follow-up results from the retrospective study previously mentioned of 377 eyes in 336 pediatric patients. (13) Of 59 eyes for which investigators had longer-term follow-up data (4 to 6.7 years), 30.9% showed worsening corrected distance visual acuity, and 24% showed corneal steepening of greater than 1 D (maximum corneal curvature). These results showed the majority of patients still experienced improvements or stabilization of keratoconus-related outcomes after corneal collagen cross-linking but suggested that long-term there may be less efficacy.

Raiskup-Wolf et al. (2008) reported on outcomes of 241 eyes (272 patients) treated with corneal collagen cross-linking, with a minimum of 6 months of follow-up. (14) Follow-up examinations were performed at 1, 6, and 12 months, and then annually. Mean follow-up was 26 months, with a range of 12 months ($n=142$) to 6 years ($n=5$). In the first year ($n=142$), steepening (maximum corneal curvature) improved or remained stable in 86% of eyes, and best-corrected visual acuity improved by at least 1 line in 53% of the eyes. Three years after treatment ($n=33$), maximum corneal curvature improved by a mean of 2.57 D in 67% of eyes while best-corrected visual acuity improved by at least 1 line in 58% of eyes. In 2015, the same group published a 10-year follow-up of corneal collagen cross-linking treatment in 34 eyes (24 patients) with progressive keratoconus. (15) Mean patient age at the time of treatment was 28

years (range, 14 to 42 years). Corneal steepening improved slightly between baseline and 10-year follow-up ($p<.001$), while corrected distance visual acuity improved by 0.14 logMAR ($p=.002$). Two eyes had repeat corneal collagen cross-linking, one after 5 years and one after 10 years, without adverse sequelae. One of the 34 eyes treated developed a permanent corneal scar. These studies were limited by their retrospective designs and the small number of cases with extended follow-up.

A publication from the Siena Eye Cross Study (2010) reported on 52-month mean follow-up (range, 48 to 60 months) for 44 keratoconic eyes treated with corneal collagen cross-linking. (16) Follow-up evaluations were performed at 1, 2, 3, 6, 12, 24, 36, 48, and 60 months after corneal collagen cross-linking. Topographic analysis showed the following mean K reading reductions: -1.96 D after 1 year, -2.12 D after 2 years, -2.24 D after 3 years, and -2.26 D after 4 years of follow-up. By comparison, in fellow eyes untreated for the first 24 months, the mean K value increased by 1.2 D at 1 year and 2.2 D at 2 years. In treated eyes, uncorrected visual acuity improved by a mean of 2.41 lines after 12 months, 2.75 lines after 24 months, 2.80 lines after 36 months, and 2.85 lines after 48 months. There was no significant decrease in endothelial cell density, central corneal thickness, or intraocular pressure over follow-up. Temporary adverse events included stromal edema in the first 30 days (70% of patients) and temporary haze (9.8% of patients). No persistent adverse events were observed.

Section Summary: Corneal Collagen Cross-Linking for Keratoconus

The evidence for epithelium-on corneal collagen cross-linking for keratoconus includes 2 RCTs. Both studies showed a significant difference between corneal cross-linking and sham treatment in maximum corneal curvature, but visual acuity results are lacking. The evidence for epithelium-off corneal collagen cross-linking for keratoconus includes RCTs, systematic reviews, and nonrandomized studies. Overall results showed long-term reduction in corneal curvature and less significant improvements in visual acuity, although some studies found significant improvement in best spectacle-corrected visual acuity up to at least 2 years.

Corneal Collagen Cross-Linking for Ectasia

Clinical Context and Therapy Purpose

Ectasia (also known as keratectasia, iatrogenic keratoconus, or secondary keratoconus) is a serious long-term complication of laser in situ keratomileusis (LASIK) surgery and photorefractive keratectomy (PRK). It is similar to keratoconus but occurs postoperatively and primarily affects older populations. It may result from unrecognized preoperative keratoconus or, less frequently, from the surgery itself. Similar to keratoconus, it is characterized by progressive thinning and steepening of the cornea, resulting in corneal optical irregularities and loss of visual acuity.

The purpose of corneal collagen cross-linking using riboflavin and ultraviolet A irradiation in individuals with ectasia is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The following PICO was used to select literature to inform this policy.

Populations

The relevant population of interest is individuals with corneal ectasia.

Intervention

The treatment being considered is corneal collagen cross-linking with riboflavin and ultraviolet A irradiation, which is performed by an ophthalmologist in an outpatient clinical setting.

Comparators

The comparators of interest are observation, rigid or specialty contact lens, intracorneal ring segments, or corneal transplant.

Outcomes

The outcomes of interest are change in disease status, functional outcomes, and treatment-related morbidity. Positive outcomes include slowing of disease progression and improvement in visual acuity and other ocular measurements. Negative outcomes include infection, adverse reactions, and need for alternative treatment, including corneal transplant.

Follow-up of at least 1 year is needed to assess outcomes.

Study Selection Criteria

Methodologically credible studies were selected using the following principles:

1. To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs.
2. In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
3. To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
4. Studies with duplicative or overlapping populations were excluded.

Systematic Reviews

The previously mentioned 2024 report from the American Academy of Ophthalmology reviewed the safety and efficacy of epithelium-off corneal collagen cross-linking for progressive corneal ectasia. (6) The analysis included 6 RCTs: 5 on progressive keratoconus and one on post-laser refractive surgery ectasia (including Wittig-Silva et al. [2014] and Hersh et al. [2017], both summarized below), with a mean follow-up of 2.4 years (range, 1 to 5 years). Although results were not statistically pooled, all studies reported reduced disease progression in treated patients versus controls and complications were rare. Treatment groups showed improvements in maximum Kmax, corrected distance visual acuity, and uncorrected distance visual acuity. Corneal thickness decreased in both groups but was more pronounced in the treatment group.

An additional systematic review with meta-analysis by Amaral et al. (2024) reviewed the safety and efficacy of corneal collagen cross-linking for managing post-laser corneal ectasia, including 15 studies (N=421; 4 RCTs and 11 nonrandomized cohorts). (17) The follow up ranged from 3 to

60 months. Pooled results showed stable uncorrected visual acuity and significant improvements in corrected distance visual acuity (SMD, 0.09; 95% CI, -0.07 to 0.26). Significant reductions were observed in spherical equivalent (SMD, -0.09; 95% CI, -0.35 to -0.02), Kmax (SMD, 0.15; 95% CI, 0.01 to 0.28), and central corneal thickness (SMD, 0.24; 95% CI, 0.07 to 0.41).

Randomized Controlled Trials

A trial reported by Hersh et al. (2017), used to inform FDA approval of Photrexa for epithelium-off corneal collagen cross-linking for the treatment of corneal ectasia, enrolled 179 patients treated for post-surgical corneal ectasia. (18) The prospective, multicenter controlled trial randomized 91 patients to treatment with standard corneal collagen cross-linking and 88 patients to a sham procedure that administered riboflavin alone and did not require the removal of the epithelium. The primary endpoint was a 1-year change in maximum corneal curvature, which was a mean 0.7 D decrease in the corneal collagen cross-linking group and a 0.6 D increase in the control group (between-group difference, 1.3 D; $p < .001$). A significantly greater improvement in corrected distance visual acuity was observed for the corneal collagen cross-linking group (5.0 logMAR gained) than for the control group (0.3 logMAR lost; $p < .001$), as was the case with uncorrected distance visual acuity, for which the between-group difference was 4.6 letters ($p < .001$). There was no significant difference between treatment and control groups for either manifest refraction spherical equivalent myopia or endothelial cell density, and fewer than 5% of eyes had adverse events. Over half of patients (68%) reported corneal stromal haze or demarcation line. The trial was limited by the last observation carried forward analysis required for the control patients who elected to receive treatment after 3 months; also, because only 4 patients received photorefractive keratectomy surgery, comparison between types of surgery and effects of postsurgery corneal collagen cross-linking were precluded.

Wittig-Silva et al. (2008) reported the first RCT of epithelium-off corneal collagen cross-linking. (19) Three-year results were published in 2014. (20) Recruitment for the trial was completed in 2009 with 50 eyes randomized to corneal collagen cross-linking treatment and 50 eyes to the untreated control. To be eligible for enrollment, clear evidence of progression of ectasia over the preceding 6 to 12 months was required. Progression was confirmed if at least one of the following criteria was met: an increase of at least 1 D in the steepest simulated maximum corneal curvature; an increase in astigmatism determined by manifest subjective refraction of at least 1 D; an increase of 0.50 D in manifest refraction spherical equivalent; or a 0.1-mm or more decrease in back optic zone radius of the best-fitting contact lens. At the time of analysis for the 2008 report, 20 eyes had reached 1-year follow-up. The 3-year results included 46 corneal collagen cross-linking treated and 48 control eyes. Last observation carried forward was used for 26 eyes, including 17 eyes from the control group with a progressive disease that underwent compassionate-use corneal collagen cross-linking or corneal transplantation. In the corneal collagen cross-linking group, there was a flattening of maximum corneal curvature by -1.03 D, compared with a 1.75 increase in maximum corneal curvature in the control group. One eye in the corneal collagen cross-linking group progressed by more than 2 D, compared with 19

eyes in the control group. Uncorrected visual acuity and best-corrected visual acuity improved in the corneal collagen cross-linking treated eyes at 1, 2, and 3 years.

Nonrandomized Studies

Margines et al. (2023) reported on outcomes of 82 eyes (54 patients) treated with epithelium-off corneal collagen cross-linking for corneal ectasia following LASIK. (21) Participants were followed prospectively with examinations performed on day 1, week 1, 1 month, 3 months, 6 months, 12 months, and then annually through 5 years. The mean follow-up was 39 months, ranging from 12 months (n=48) to 5 years (n=19). Patients had a mean age of 42.8 years and underwent corneal cross-linkage after an average of 11.4 ± 4.65 years following LASIK surgery with an average spherical equivalent fraction of -2.08. After treatment, the spherical equivalent did not change significantly. From pre-corneal cross-linkage values to 5 years follow-up, logMAR uncorrected visual acuity improved from 0.78 ± 0.35 to 0.63 ± 0.32 ($p > .05$), and logMAR corrected distance visual acuity improved from 0.29 ± 0.17 to 0.25 ± 0.26 ($p > .05$). Steep keratometry improved significantly from pre-operation (49.0 ± 4.3 D) to one year post-operatively (45.5 ± 1.9 D; $p < .0125$) and remained stable through 5-year follow-up (47.2 ± 3.0 D; $p < .0125$). The authors reported no surgical complications, and no patient underwent additional treatment. Post-operative corneal haze was reported as occurring occasionally, but the number of eyes was not reported. This study was limited by a lack of experimental design and the small number of cases with extended follow-up.

Section Summary: Corneal Collagen Cross-Linking for Ectasia

Evidence for epithelium-off corneal collagen cross-linking for corneal ectasia includes 2 systematic reviews, 2 RCTs, and one prospective, single-arm cohort study. Results showed improvement in uncorrected distance visual acuity, corrected distance visual acuity, best spectacle-corrected visual acuity, and maximum corneal curvature compared to sham after at least 12 months. In addition, a higher proportion of participants in the corneal collagen cross-linking group had a ≥ 15 -letter improvement with best spectacle-corrected visual acuity than in the sham group. Five-year follow-up in a prospective cohort study found sustained improvement in uncorrected and corrected distance visual acuity scores as well as steep keratometry from baseline levels with no significant change in spherical equivalent.

Adverse Events

A safety analysis conducted by the FDA included 512 eyes (293 eyes with keratoconus, 219 eyes with corneal ectasia) in 364 patients who received epithelium-off corneal collagen cross-linking treatment. (22) As described earlier, the procedure involves removing the corneal epithelium to enhance the riboflavin solution's penetration. As a result, patients may develop a range of ocular adverse reactions, including corneal opacity (haze), corneal epithelial defects, punctate keratitis, corneal striae, eye pain, reduced visual acuity, blurred vision, dry eye, and photophobia among others. Most adverse events resolved in the first month, while others took up to 12 months to resolve. However, in 1% to 6% of patients, these adverse events could continue beyond 12 months.

Summary of Evidence

For individuals who have progressive keratoconus who receive corneal collagen cross-linking using riboflavin and ultraviolet A, the evidence includes randomized controlled trials (RCTs), systematic reviews, and nonrandomized studies. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. For epithelium-on corneal collagen cross-linking, 2 RCTs showed a significant difference between corneal cross-linking and sham treatment in maximum corneal curvature, but visual acuity results are lacking. Based on RCT evidence used to inform U.S. Food and Drug Administration (FDA) approval, epithelium-off corneal collagen cross-linking was associated with significant improvements in corneal curvature score and corrected distance visual acuity and non-significant improvement in uncorrected distance visual acuity compared with sham treatment after 1 year of follow-up. Long-term RCT follow-up is needed. Several non-randomized studies measured visual acuity and found significant and lasting improvements in corrected visual acuity and other measures with corneal collagen cross-linking. The adverse events associated with epithelium-off corneal collagen cross-linking include corneal opacity (haze), corneal epithelial defects, and other ocular findings. Most adverse events resolved in the first month but continued in a few (1% to 6%) patients for 6 to 12 months. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have corneal ectasia after refractive surgery who receive corneal collagen cross-linking using riboflavin and ultraviolet A, the evidence includes systematic reviews and RCTs. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. Systematic reviews demonstrate that corneal collagen cross-linking is effective in reducing the progression of keratoconus and post-laser refractive surgery ectasia. Randomized controlled trial evidence, used to inform FDA approval, found that corneal collagen cross-linking was associated with significant improvements in corneal curvature score, corrected distance visual acuity, and uncorrected distance visual acuity after 1 year follow-up when compared with sham treatment. Another trial that followed patients up to 3 years saw continued improvement in visual acuity with corneal collagen cross-linking. Five-year follow-up in a prospective single-arm study found sustained improvement in uncorrected and corrected distance visual acuity scores and steep keratometry from baseline levels with no significant change in spherical equivalent. Additional long-term follow-up for visual acuity outcomes is needed. The adverse events associated with corneal collagen cross-linking were the same for the ectasia trials as for the keratoconus trials. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Practice Guidelines and Position Statements

National Institute for Health and Care Excellence (NICE)

In 2013, the NICE issued guidance on corneal collagen cross-linking using riboflavin and ultraviolet A, updating its guidance based on a 2009 systematic review of primarily low-quality evidence; review authors declared no financial conflicts of interest. (23) The 2013 guidance stratified recommendations for corneal collagen cross-linking as follows:

“Most of the published evidence on photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A (UVA) for keratoconus and keratectasia relates to the technique

known as ‘epithelium-off corneal collagen cross-linking.’ ‘Epithelium-on (transepithelial) corneal collagen cross-linking’ is a more recent technique and less evidence is available on its safety and efficacy. Either procedure (epithelium-off or epithelium-on corneal collagen cross-linking) can be combined with other interventions, and the evidence base for these combination procedures (known as ‘corneal collagen cross-linking plus’) is also limited. Therefore, different recommendations apply to the variants of this procedure, as follows.

1.1 Current evidence on the safety and efficacy of epithelium-off corneal collagen cross-linking for keratoconus and keratectasia is adequate in quality and quantity. Therefore, this procedure can be used provided that normal arrangements are in place for clinical governance, consent and audit.

1.2 Current evidence on the safety and efficacy of epithelium-on (transepithelial) corneal collagen cross-linking, and the combination (corneal collagen cross-linking plus) procedures for keratoconus and keratectasia is inadequate in quantity and quality. Therefore, these procedures should only be used with special arrangements for clinical governance, consent and audit or research.”

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this policy are listed in Table 5.

Table 5. Summary of Key Trials

NCT Number	Trial Name	Planned Enrollment	Completion Date
NCT07135167	Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome	225	Feb 2026
NCT01112072	Randomized Study of Safety and Efficacy of Corneal Collagen Crosslinking and Intacs for Treatment of Keratoconus and Corneal Ectasia	160	Dec 2025
NCT03319082 ^a	A Phase IV Observational Registry to Assess the Durability of Effect of Corneal Collagen Cross-linking With Photrexa Viscous, Photrexa, and the KXL System in Patients With Corneal Ectasia Following Refractive Surgery	200	Feb 2026
NCT01604135	Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial	36	Apr 2025

NCT03760432	Clinical Trial of Laser Custom Corneal Collagen Cross-Linking in Keratoconus	100	Dec 2027
NCT00560651	German Corneal Cross-Linking Registry	7500	Nov 2027
NCT01708538 ^a	Phase III Study of Corneal Collagen Cross-linking Using Two Different Techniques	30	Oct 2024
NCT04213885	Safety and Effectiveness of the PXL Platinum 330 System for Corneal Collagen Cross-Linking in Eyes With Corneal Thinning Position	12	Aug 2024
NCT03531047	A Prospective, Controlled Study of Refractive Corneal Cross-linking for Progressive Keratoconus	53	Nov 2021

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

Coding

Procedure codes on Medical Policy documents are included **only** as a general reference tool for each policy. **They may not be all-inclusive.**

The presence or absence of procedure, service, supply, or device codes in a Medical Policy document has no relevance for determination of benefit coverage for members or reimbursement for providers. **Only the written coverage position in a Medical Policy should be used for such determinations.**

Benefit coverage determinations based on written Medical Policy coverage positions must include review of the member's benefit contract or Summary Plan Description (SPD) for defined coverage vs. non-coverage, benefit exclusions, and benefit limitations such as dollar or duration caps.

CPT Codes	0402T
HCPCS Codes	C9399, J2787, J2789, J3490

*Current Procedural Terminology (CPT®) ©2025 American Medical Association: Chicago, IL.

References

1. American Academy of Ophthalmology. Corneal Collagen Cross-Linking. December 2, 2025. Available at <<https://www.aao.org>> (accessed December 26, 2025).
2. Avedro Inc. Avedro Briefing Package for Joint Meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Device Panel of the Medical Devices Advisory Committee NDA 203324: Photrex Viscous and Photrex (riboflavin ophthalmic solution) and KXL System (UVA light source) Avedro, Inc. 2016. Available at <<https://www.accessdata.fda.gov>> (accessed December 26, 2025).
3. Davis LJ, Schechtman KB, Wilson BS, et al. Longitudinal changes in visual acuity in keratoconus. Invest Ophthalmol Vis Sci. Feb 2006; 47(2):489-500. PMID 16431941
4. McMahon TT, Edrington TB, Szczotka-Flynn L, et al. Longitudinal changes in corneal curvature in keratoconus. Cornea. Apr 2006; 25(3):296-305. PMID 16633030
5. Epioxa HD and Epioxa. Package insert. Glaukos Corporation; October 2025. Available at <<https://www.epioxa.com>> (accessed January 7, 2026).

6. Cortina MS, Greiner MA, Kuo AN, et al. Safety and Efficacy of Epithelium-Off Corneal Collagen Cross-Linking for the Treatment of Corneal Ectasia: A Report by the American Academy of Ophthalmology. *Ophthalmology*. Oct 2024; 131(10):1234-1242. PMID 38935041
7. McAnena L, Doyle F, O'Keefe M. Cross-linking in children with keratoconus: a systematic review and meta-analysis. *Acta Ophthalmol*. May 2017; 95(3):229-239. PMID 27678078
8. Hersh PS, Stulting RD, Muller D, et al. United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment. *Ophthalmology*. Sep 2017; 124(9):1259-1270. PMID 28495149
9. Toprak I, Yaylali V, Yildirim C. Visual, topographic, and pachymetric effects of pediatric corneal collagen cross-linking. *J Pediatr Ophthalmol Strabismus*. Mar 01 2017; 54(2):84-89. PMID 27668869
10. Badawi AE. Accelerated corneal collagen cross-linking in pediatric keratoconus: One year study. *Saudi J Ophthalmol*. 2017; 31(1):11-18. PMID 28337057
11. Knutsson KA, Paganoni G, Matuska S, et al. Corneal collagen cross-linking in paediatric patients affected by keratoconus. *Br J Ophthalmol*. Feb 2018; 102(2):248-252. PMID 28655729
12. Papaioannou L, Miligkos M, Papathanassiou M. Corneal Collagen Cross-Linking for Infectious Keratitis: A Systematic Review and Meta-Analysis. *Cornea*. Jan 2016; 35(1):62-71. PMID 26509768
13. Padmanabhan P, Rachapalle Reddi S, Rajagopal R, et al. Corneal collagen cross-linking for keratoconus in pediatric patients-long-term results. *Cornea*. Feb 2017; 36(2):138-143. PMID 28060058
14. Raiskup-Wolf F, Hoyer A, Spoerl E, et al. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. *J Cataract Refract Surg*. May 2008; 34(5):796-801. PMID 18471635
15. Raiskup F, Theuring A, Pillunat LE, et al. Corneal collagen crosslinking with riboflavin and ultraviolet-A light in progressive keratoconus: ten-year results. *J Cataract Refract Surg*. Jan 2015; 41(1):41-46. PMID 25532633
16. Caporossi A, Mazzotta C, Baiocchi S, et al. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. *Am J Ophthalmol*. Apr 2010; 149(4):585-593. PMID 20138607
17. Amaral DC, Menezes AHG, Vilaça Lima LC, et al. Corneal Collagen Crosslinking for Ectasia After Refractive Surgery: A Systematic Review and Meta-Analysis. *Clin Ophthalmol*. Mar 19 2024; 18:865-879. PMID 38525385
18. Hersh PS, Stulting RD, Muller D, et al. U.S. multicenter clinical trial of corneal collagen crosslinking for treatment of corneal ectasia after refractive surgery. *Ophthalmology*. Oct 2017; 124(10):1475-1484. PMID 28655538
19. Wittig-Silva C, Whiting M, Lamoureux E, et al. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. *J Refract Surg*. Sep 2008; 24(7):S720-725. PMID 18811118
20. Wittig-Silva C, Chan E, Islam FM, et al. A randomized, controlled trial of corneal collagen cross-linking in progressive keratoconus: three-year results. *Ophthalmology*. Apr 2014; 121(4):812-821. PMID 24393351

21. Margines JB, Rabinowitz YS, Li X, et al. Results of corneal collagen cross-linking in patients with corneal ectasia after laser refractive surgery-A prospective study. Photodiagnosis Photodyn Ther. Jun 2023; 42:103521. PMID 36931367
22. Center for Drug Evaluation and Research. Application Number 203324Orig2s000. Summary Review. 2015. Available at <<https://www.accessdata.fda.gov>> (accessed December 26, 2025).
23. National Institute for Health and Clinical Excellence (NICE). Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia [IPG466]. 2013; Available at <<https://www.nice.org.uk>> (accessed December 26, 2025).

Centers for Medicare and Medicaid Services (CMS)

The information contained in this section is for informational purposes only. HCSC makes no representation as to the accuracy of this information. It is not to be used for claims adjudication for HCSC Plans.

The Centers for Medicare and Medicaid Services (CMS) does not have a national Medicare coverage position. Coverage may be subject to local carrier discretion.

A national coverage position for Medicare may have been developed since this medical policy document was written. See Medicare's National Coverage at <<https://www.cms.hhs.gov>>.

Policy History/Revision

Date	Description of Change
05/01/2026	Document updated. The following change was made to Coverage: Added "NOTE: Two corneal collagen cross-linking products were available for treatment of progressive keratoconus and corneal ectasia – Photrexa and Epioxa. Photrexa products are planned to be discontinued from the market effective January 20, 2026 with manufacturing set to end February 2026." Added reference 5; other(s) updated.
08/01/2025	Document updated with literature review. Coverage reorganized with movement of some criteria to Policy Guidelines; no change to policy intent. Added references 1, 5, and 16.
11/15/2024	Document updated with literature review. Coverage unchanged. Added reference 17.
12/01/2023	Document updated with literature review. Coverage unchanged. No new references added.
07/15/2022	Reviewed. No changes.
07/15/2021	Document updated with literature review. Coverage unchanged. References updated.
06/15/2020	Reviewed. No changes.
08/01/2019	Document updated with literature review. Coverage unchanged. Added references: 10, 12, 18-20.

06/15/2018	Reviewed. No changes.
11/01/2017	Document updated with literature review. The following changes were made to Coverage: 1) Corneal collagen cross-linking using riboflavin and ultraviolet A may be considered medically necessary as a treatment of progressive keratoconus or corneal ectasia after refractive surgery. 2) Corneal collagen cross-linking using riboflavin and ultraviolet A is considered experimental, investigational, and/or unproven for all other indications. 3) A specific definition of progressive keratoconus or corneal ectasia was added.
07/15/2016	Document updated with literature review. Coverage unchanged.
07/15/2015	Reviewed. No changes.
11/15/2014	New medical document. Corneal collagen cross-linking is considered experimental, investigational and/or unproven for all indications.